Rob is Senior Vice President, Global Development, responsible for the clinical development of Amgen’s portfolio. He joined Amgen in 2012 to lead the Neuroscience development programs, including AMG 334 (Aimovig). Rob assumed roles of increasing responsibility including leadership of the Inflammation and Nephrology therapeutic areas. He created a quantitative science organization, the Center for Design and Analysis, that drives innovative study designs and analysis, established a data science capability, and a data-driven approach to decision making across the pipeline. He was promoted to Senior Vice President of Global Development in June of 2020.

Prior to joining Amgen, Rob spent 9 years at Abbott, ultimately serving as the Therapeutic Area head and Vice President of Neurology, Psychiatry and Anesthesiology. During his tenure at Abbott and Amgen he has been responsible for the development of multiple globally approved medicines. Rob received his MD, PhD with honors from the University of Maryland, with a research focus in Neuropharmacology. He then completed his residency in Neurology at UCLA.